Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trevena's Intravenous Opioid Will Face Difficult US FDA Advisory Committee

Executive Summary

Oliceridine is not superior to morphine, has abuse potential similar to other mu opioid agonists, FDA concludes; also endpoint Trevena used to evaluate respiratory safety was inadequate, FDA says.

You may also be interested in...



Keeping Track: FDA Starts November With A Bang

The latest drug development news and highlights from our FDA Performance Tracker.

Trevena's IV Opioid Not Quite 'Ready for Primetime,' US FDA Panel Concludes

Advisory committee votes 8-7 against approval of the novel opioid; several members say they would change their vote with more data.

After APOLLO: Trevena Weighs Commercial Viability Of Opioid Oliceridine

A mixed bag of safety results for the new opioid Olinvo (oliceridine) in the Phase III APOLLO pain trials disappoints the market, but analysts are encouraged by the totality of the data and optimistic about approval.

Topics

Related Companies

UsernamePublicRestriction

Register

PS124036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel